| We investigated the real-word application of ixekizumab, a monoclonal antibody against interleukin-17A, in China. |
| Ixekizumab was well tolerated and effective in routine clinical practice in Chinese adults with moderate-to-severe plaque psoriasis. |
| No new safety signals were observed and the safety profile of ixekizumab was consistent with that of previous clinical trials. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.